IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE

• 1. 抗程序性死亡配体-1(PD-L1)抗体的抗肿瘤用途 [P] . 中国专利： CN112672759A . 2021-04-16
• 2. 一种程序性死亡受体-配体1的核酸适体检测细胞外囊泡表面PD-L1蛋白的方法 [P] . 中国专利： CN110108885B . 2020.10.09
• 3. IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE [P] . EP2981821B2 . 2021-11-03

  机译： 用于检测肿瘤组织中编程死亡配体1（PD-L1）的表达的免疫组织化学测定

• 4. Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue [P] . US11193937B2 . 2021-12-07

  机译： 用于检测肿瘤组织中编程死亡配体1（PD-L1）的表达的免疫组织化学测定

• 5. IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE [P] . 美国专利： US2018080938A1 . 2018-03-22

  机译： 检测肿瘤组织中已编程死亡配体1（PD-L1）表达的免疫组织化学分析

• 1. Correlation of Programmed Death Ligand-1 (PD-L1) Expression with Clinicopathological Features in Non-Small Cell Lung Carcinoma: Experience from a Tertiary Cancer Care Center in India [J] . Hafsa Saif, K. S. Rajesh Kumar, Suhail Sayeed Mufti, 癌症治疗（英文） . 2020,第003期
• 2. Expression and clinical value of programmed cell death-ligand 1(PD-L1)in diffuse large B cell lymphoma:a retrospective study [J] . Li-Yang Hu, Qing-Qing Cai, Xiao-Lu Xu, 癌症（英文版） . 2017,第012期
• 3. Programmed cell death ligand-1 （PD-L1） expression by immunohistochemistry： could it be predictive and/or prognostic in non-small cell lung cancer？ [J] . Mari Mino-Kenudson 癌症生物学与医学：英文版 . 2016,第002期
• 4. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry：could it be predictive and/or prognostic in non-small cell lung cancer? [J] . Mari Mino-Kenudson 癌症生物学与医学（英文版 ） . 2016,第002期
• 5. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1) Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors [J] . Inaguma Shingo, Wang Zengfeng, Lasota Jerzy, American Journal of Surgical Pathology . 2016,第8期
• 6. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy [J] . Katsuya Yuki, Horinouchi Hidehito, Asao Tetsuhiko, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期
• 7. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy [J] . Katsuya Yuki, Horinouchi Hidehito, Asao Tetsuhiko, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期
• 8. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019
• 9. Glioblastoma-Derived Interleukin-6 Induces Immunosuppressive Peripheral Myeloid Programmed Death-Ligand 1 Expression and Tumor Growth [D] . Lamano, Jonathan Balquiedra. 2019
• 10. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1). Analysis in 5536 cases revealed consistent expression in trophoblastic tumors [O] . Shingo Inaguma, Zengfeng Wang, Jerzy Lasota, -1
• 11. Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types [O] . Giosuè Scognamiglio, Anna De Chiara, Maurizio Di Bonito, 2016

• 1. Prognostic value of programmed death.1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1.4N+M0 gastric adenocarcinoma [J] . Yuan Gao ,Su Li ,Dazhi Xu . 癌症 . 2017,第11期
• 2. 免疫组织化学在乳腺导管内增生性病变、乳头状肿瘤和小叶肿瘤中的应用 [C] . 步宏 ,魏兵 ,李新军 . 第六届全国诊断病理暨基础病理学术研讨会 . 2005
• 3. 采用组织芯片技术检测P选择素及其配体在人类食管肿瘤中的表达及意义 [A] . 阎齐 . 2003